282 Successful Treatment of Severe Nonallergic Asthma by Omalizumab. An Observation
نویسندگان
چکیده
apply to them, it applying for 6 month. Results: All the patient improved their Urticaria between weeks 3 and fort of application of the drug, getting the control of the symptoms between the month 2 and 3 in the 5 patients, without requiring other drugs for their control, and remained asymptomatic for 3 and forth months discontinuity the product up to 6 months, not reactivity the Urticaria, the older case takes now 1 year without activity of his disease. Conclusions: Omalizumab must be considered to be another therapeutic alternative in patients with idiopathic Urticaria.
منابع مشابه
Benefits of omalizumab on anxiety and depression in patients with severe asthma
Background: Asthma is one of the most common chronic diseases and may cause psychiatric disorders affecting the patients’ quality of life. In our study, we evaluated the effect of omalizumab treatment on anxiety disorder and depression using Beck Depression Scale (BDS) and State Trait Anxiety Inventory (STAI). Methods: Anxiety level was determined with STAI, whereas depression level was ...
متن کاملApsr Respiratory Updates
Monitoring free serum IgE in severe asthma patients treated with omalizumab. 2 Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. 2 Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. 3 A genome-wide association study of plasma total IgE concentrations in the Framingham Heart Study. 4 Reduction of total Ig...
متن کاملOmalizumab, an anti-immunoglobulin E antibody: state of the art
A large number of trials show that the anti-immunoglobulin (Ig) E antibody omalizumab is very effective in patients with severe allergic asthma. This is acknowledged in consensus documents. The drug also has a good safety profile and a pharmacoeconomic advantage due to a reduction in the number of hospitalizations for asthma attacks. In recent years, some studies have shown that omalizumab is e...
متن کاملClinical experience with omalizumab in a Portuguese severe asthma unit.
BACKGROUND It is widely recognized that asthma control is not always possible in patients with very severe asthma despite available treatment. The aim of this study was to evaluate the efficacy of Omalizumab on asthma control as an add-on therapy in patients from the "Severe Asthma Outpatient Clinic" of Pulido Valente Hospital in Lisbon, Portugal. METHODS A retrospective study was conducted t...
متن کاملEfficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study
BACKGROUND Omalizumab (Xolair®), a recombinant monoclonal anti-IgE antibody, has demonstrated efficacy in clinical trials conducted in patients with moderate to severe persistent allergic asthma. We aimed to investigate the efficacy, discontinuation and medical resource utilization of omalizumab in the real-life setting in Taiwan. METHODS This study was a retrospective, population-based datab...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 5 شماره
صفحات -
تاریخ انتشار 2012